Assessment of the Prognostic Relevance of Serum Anti-p53 Antibodies in Epithelial Ovarian Cancer
- 31 January 1999
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 72 (1), 76-81
- https://doi.org/10.1006/gyno.1998.5101
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Circulating antibodies against p53 protein in patients with ovarian carcinomaCancer, 1996
- Cisplatin-induced apoptosis andp53 gene status in a cisplatin-resistant human ovarian carcinoma cell lineInternational Journal of Cancer, 1996
- Serum Half-Life of CA 125 during Early Chemotherapy as an Independent Prognostic Variable for Patients with Advanced Epithelial Ovarian Cancer: Results of a Multicentric Italian StudyGynecologic Oncology, 1995
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- Antibodies Against Autologous Tumor Cell Proteins in Patients With Small-Cell Lung Cancer: Association With Improved SurvivalJNCI Journal of the National Cancer Institute, 1993
- Clinical Implications of the p53 Tumor-Suppressor GeneNew England Journal of Medicine, 1993
- A death in the life of p53Nature, 1993
- p53, guardian of the genomeNature, 1992
- TP53 tumor suppressor gene: A model for investigating human mutagenesisGenes, Chromosomes and Cancer, 1992
- p53 Mutations in Human CancersScience, 1991